Open-label RCT in 45 adults with type 2 diabetes at high cardiovascular risk: 26 weeks of canagliflozin vs sitagliptin reduced CMR-measured extracellular volume, a marker of myocardial fibrosis (adjusted mean difference -3.67%), with similar HbA1c falls.
RCTn = 45
Yan et al. Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial